Navigation Links
Experimental Alzheimer’s Drug curbs the disease in mic

Frank LaFerla, a professor of neurobiology at the University of California, Irvine (UCI) and also the senior author in the research said that the experimental drug// AF267B is effective against both forms of brain lesions found in Alzheimer's disease in mice.

This compound (AF267B) curbs both the amyloid protein plaques that collect in Alzheimer's-affected brains, as well as another lesion, the tangles of protein called tau.

In mice that have been genetically designed to mimic Alzheimer's disease AF267B also appears to reverse cognitive declines. Researchers said that the mice appeared to gain renewed powers of memory and learning after treatment. The findings of the study were reported in the journal Neuron.

AF267B is a perfect drug for the Alzheimer's disease. It has the disease-modifying capacity that treats the symptoms and also reverses the cognitive declines. Frank LaFerla said that AF267B is an M1 agonist. It acts by stimulating the muscarinic receptor which is present on the surface of nerve cells.

In the Alzheimer's disease there is a selective loss of neurons which produce the neurotransmitter acetylcholine. He said that by stimulating the M1 receptor one can boost the acetylcholine activity and AF267B does the stimulation. It was developed by the famous Alzheimer's researcher and study co-author Abraham Fisher, of the Israel Institute for Biological Research, in Ness-Ziona, Israel.

But all this was possible only because of the genetically designed mouse. This mouse mimics human Alzheimer's disease more closely than any previous rodent strain. That's because these mice develop both plaques and tangles whereas the previous models failed to develop tangles.

William Thies, vice president of medical and scientific affairs at the Alzheimer's Association said that this research is the stepping stone to find the cure for human Alzheimer's disease. LaFerla said that in these mice models it was found that
'"/>




Page: 1 2

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. Experimental drug to fight flu
3. Experimental SARS Vaccine
4. Experimental vaccine for shingles is effective
5. Experimental Blood Test May Spot Heart Attack Risk, Study Says
6. Five AIDS Patients To Receive Experimental Anti-retroviral Drugs
7. Protection against HIV and Herpes is possible with the Experimental Microbicide
8. Experimental Therapy Effective Against Malignant Melanoma in Horses
9. New Guidelines to Be Laid While Testing Experimental Drugs
10. Experimental Drug Deals Effectively with Prostate Cancer Cells
11. Experimental Drug Causes Cytokine Storm
Post Your Comments:
(Date:10/10/2008)..., Oct. 10 /PRNewswire/ -- A senior citizen,soared ...ns in a small,plane. The high-flying adventure was...thrill came from a last-wish program through Silve...iving, where Heden was a patient.,Called Go Wish, ... helped,many realize a special activity at the end...
(Date:10/10/2008)...careful screening for these patients, researcher s... -- Patients coping with metabolic syndrome have a...cancer sometime in their lives, a new study sugges...f three or four diseases, that together can porten...ng a number of cancers," said study co-author Dr. ...
(Date:10/10/2008)...er (BMC) has received a $5,807,469 grant over five...to fund the Boston Claude D. Pepper Older American...of only 11 Pepper Centers in the country. , The...ter Program was established in honor of Claude D. ... his five decades of public service, Pepper was an...
(Date:10/10/2008)...ire/ -- A nationally recognized faculty will,prese...ts with breast,cancer in the multimedia course "Op...iomarkers to Treatment Selection" during National ... for practicing oncologists and other interested,h...est patient care,advances. This accredited course ...
Breaking Medicine News(10 mins):Health News:Deck of Cards is More Than a Game: Integral in Silverado Hospice Care 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 3Health News:Boston Medical Center receives $5.8m grant 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...on called contact dermatitis may benefit from ridd... tomatoes, according to the results of a small stu...ce inflamed, red, itchy, scaly skin when they come.... The reaction is usually associated with an aller...
...ient in the -- depo medroxyprogesterone acetate or... long term. The younger you are when you begin usi...ne-related problems later in life. // From the ..., our bone mass is constantly breaking down and re...
...with testicular cancer may inadvertently increase ...rs.A research team from North Carolina University ...s go down, a high rise in levels of amyloid – the ...ccurs. They suggest that this phenomenon might exp...
...d if all pregnant women stopped smoking, say Austr...rs need much more support and training in helping ...k of having a low birth weight baby, a miscarriage... SIDS - and if women are not able to give up entir...
Other Medicine News:
(Date:10/7/2008)...Study Showed Larazotide Acetate Prevented Immunolo...atients with Celiac Disease, Additional Data Indic...ase, ORLANDO, Fla., Oct. 7 /- Alba T... clinical studies this week at the American,Colleg... Meeting. Data from,study CLIN 1001-004, the first...
(Date:10/7/2008)... FORT COLLINS, Colo., Oct. 7 /- A st...mining embryonic stem cell self-renewal,reported ...tim (recombinant,human serum albumin) was an effec...l culture., The article entitled, "The ground sta... that researchers used Cellastim as a recombinant,...
(Date:10/7/2008)... BERKELEY, Calif., Oct. 7 /- Aerovan...fety data from a Phase I trial of its Aerovant,inh...with no evidence of,local irritancy following asth...This 10 mg dose will be the highest of three doses...g study, which is scheduled to begin early,next ye...
(Date:10/7/2008)... SAN DIEGO, Oct. 7 /- Arde...ay that a poster entitled "RDEA119, a Potent,and H...Dextran Sulfate,Sodium (DSS) -- induced Chronic Co...ege of Gastroenterology (ACG) 2008 Annual Meeting ...ta from a preclinical study of,RDEA119, the Compan...
Breaking Medicine Technology:Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4NeoGenomics to Present at the Noble Financial Equity Conference 25367 1NeoGenomics to Present at the Noble Financial Equity Conference 25367 2Courage Center Seeks Applications for Judd Jacobson Memorial Award 25364 1Courage Center Seeks Applications for Judd Jacobson Memorial Award 25364 2REMOXY 28R 29 NDA Filing Accepted by FDA and Priority Review Granted 2827 1REMOXY 28R 29 NDA Filing Accepted by FDA and Priority Review Granted 2827 2REMOXY 28R 29 NDA Filing Accepted by FDA and Priority Review Granted 2827 3New Test Scans Beef for Mad Cow Disease 25361 1New Test Scans Beef for Mad Cow Disease 25361 2
...ESS WIRE)--Jun 21, 2007 - Opexa,Therapeutics, Inc....ent and commercialization of cell therapies, today... Phase I/II,extension clinical trial of the invest...e sclerosis (MS). In this one-year,8-subject exte...,and secondary progressive (SPMS) subjects, Tovaxi...
...ne 21, 2007 - “In anaplastic,astrocytoma, AP...or,to temozolomide,” Prof. Albert Wong, M.D....d on the international Phase,IIb study with the TG...Antisense Pharma. Prof. Wong discussed the results...central nervous system tumors,at the 43rd Annual M...
Other Medicine Technology:Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 2Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 3Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 4Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 5Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 2Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 3Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 4
...illennium, the newest entry in the Beehive product...monitoring with the technology of the 21st century...igital Video/EEG instrument, providing complete da...that are specialized for epilepsy monitoring appli...
...ncludes 16 electrodes with ball joint, and flexi...r electrode assembly, with 16 female support for b... electrodes. 2 individual electrodes with flexib.... Drill to hole skull. Mounting post. Key to...
Medelec synergy T-EP Developed in collaboration with leading practitioners, for ease of use and an exceptionally high standard of clinical testing, Synergy T-EP harnesses PC Multimedia technology and
Neuropack MEB-2200 evoked potential/EMG measuring system is user friendly Windows NT, Pentium III PC-based EP/EMG measuring system.
Medicine Products: